Posts Tagged ‘Op-ed-VT-S175’
Economic Policy Researcher Finds Fault with Federal Drug Importation Plans
This editorial by Liam Sigaud was published by Inside Sources on August 27, 2019. Mr. Sigaud is an economic policy researcher who writes for the American Consumer Institute, a nonprofit educational and research organization.
[...]Cancer Center Pharmacist in Iowa Worries Drug Importation Will Harm His Patients
This editorial by Dana McDougall was published in The Waterloo Cedar Falls Courier on August 26, 2019. Mr. McDougall, Pharm.D., BCPS, is a pharmacist with the Covenant Cancer Treatment Center in Waterloo, Iowa.
[...]Drug Distribution Experts Warn That State Plans To Import Foreign Drugs Will Undermine Safety
This editorial by Adam Fein and Dirk Rodgers was published in Stat News on July 11, 2019. In it, Fein and Rodgers warn that plans by states to create drug importation programs will open new pathways for counterfeit drugs to enter the U.S. drug supply chain…
[...]“Canada cannot act as a drugstore for the United States,” says academic
In this editorial, which was published by the Fraser Institute on June 13, 2019, economist Dr. Kristina Acri argues against importation, concluding: “Diverting drugs meant for Canadian patients to the U.S. through state importation schemes will create shortages for Canadian patients and increase pressure on potentially unscrupulous suppliers to source drugs from wherever they can, opening the door to counterfeiters.”
[...]Canadian Policy Researcher Warns That Importation Plans By U.S. States Would Leave Canada Without Crucial Medicines
This editorial by Nigel Rawson was published in The Hills Times on June 9, 2019. Dr. Rawson, president of Eastlake Research Group, a senior fellow at the Fraser Institute, and an affiliated scholar with the Canadian Health Policy Institute, warns that Canada would run out of necessary medicine if U.S. states begin drug importation programs…
[...]The case against importation: “There are simply too many channels for fake drugs to enter any importation scheme”
In this piece, which was published in the Inside Sources on April 22, 2019, Michael Graham reviews the case against drug importation: “As Scott Gottlieb said in 2016 before becoming President Trump’s FDA chief…’There are simply too many channels for fake drugs to enter any importation scheme to forgo some meaningful controls.’”
[...]The Wall Street Journal’s Editorial Board Comes Out Against Drug Importation
The editorial board of the The Wall Street Journal published this editorial on April 15, 2019. In it, they write:
“The argument that drug importation threatens the integrity of the drug supply is often dismissed because pharmaceutical lobbyists make it. But keeping the drug supply free from contaminated or counterfeit products is not easy, and the World Health Organization has warned that 1 in 10 medical products in the developing world are phony. It isn’t clear who is liable if counterfeits are found in Florida, but you can bet it won’t be the politicians.”
[...]Vermont: Still #1 in Dumb Healthcare Ideas
Earlier this month, in the midst of an opioid epidemic ravaging the state, Vermont’s legislature voted to legalize buying drugs from Canada, where government-set price controls keep prices artificially low.
[...]Wholesale Drug Importation From Canada Won’t Lower Prices, But Will Increase Health Risks Says Vermonter
By approving the wholesale reimportation of U.S. prescription drugs from Canada, the Vermont Legislature passed an illegal measure that will not lower drug prices. Instead, it will subject Vermonters to public health risks and new taxes to defray an inevitable federal lawsuit.
[...]